Preclinical Development of a Prophylactic Neuroprotective Therapy for the Preventive Treatment of Anticipated Ischemia-Reperfusion Injury

Frances Bahjat, G. Alexander West, Steven Kohama, Christine Glynn, Henryk Urbanski, Theodore Hobbs, Eric Earl, Susan L. Stevens, Mary Stenzel-Poore

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Ischemia-reperfusion brain injury can be iatrogenically induced secondary to life-saving procedures. Prophylactic treatment of these patients offers a promising prevention for lifelong complications. We postulate that a cytosine-guanine (CpG) oligodeoxynucleotide (ODN) can provide robust antecedent protection against cerebral ischemic injury with minimal release of pro-inflammatory cytokines, making it an ideal candidate for further clinical development. Mouse and nonhuman primate (NHP) models of cerebral ischemic injury were used to test whether an A-type CpG ODN, which induces minimal systemic inflammatory cytokine responses, can provide prophylactic protection. Extent of injury in the mouse was measured by histological staining of live tissue. In the NHP, injury was assessed 2 and 7 days post-occlusion from T2-weighted magnetic resonance images and neurological and motor deficits were cataloged daily. Plasma cytokine levels were measured using species-specific Luminex assays. Prophylactic administration of an A-type CpG ODN provided robust protection against cerebral ischemic injury in the mouse with minimal systemic inflammation. Rhesus macaques treated with D192935, a mixture of human optimized A-type CpG ODNs, had smaller infarcts and demonstrated significantly less neurological and motor deficits following ischemic injury. Our findings demonstrate the translational potential of D192935 as a prophylactic treatment for patients at risk of cerebral ischemic injury.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalTranslational Stroke Research
DOIs
StateAccepted/In press - Apr 5 2017

Fingerprint

Reperfusion Injury
Wounds and Injuries
Oligodeoxyribonucleotides
Cytokines
Primates
Therapeutics
Cytosine
Guanine
Macaca mulatta
Brain Injuries
Magnetic Resonance Spectroscopy
Staining and Labeling
Inflammation

Keywords

  • CpG ODN
  • Ischemia
  • Neuroprotection
  • Nonhuman primate
  • Preconditioning
  • Stroke

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Preclinical Development of a Prophylactic Neuroprotective Therapy for the Preventive Treatment of Anticipated Ischemia-Reperfusion Injury. / Bahjat, Frances; Alexander West, G.; Kohama, Steven; Glynn, Christine; Urbanski, Henryk; Hobbs, Theodore; Earl, Eric; Stevens, Susan L.; Stenzel-Poore, Mary.

In: Translational Stroke Research, 05.04.2017, p. 1-12.

Research output: Contribution to journalArticle

@article{83d169846c664e7c9321ccaa22d86ffc,
title = "Preclinical Development of a Prophylactic Neuroprotective Therapy for the Preventive Treatment of Anticipated Ischemia-Reperfusion Injury",
abstract = "Ischemia-reperfusion brain injury can be iatrogenically induced secondary to life-saving procedures. Prophylactic treatment of these patients offers a promising prevention for lifelong complications. We postulate that a cytosine-guanine (CpG) oligodeoxynucleotide (ODN) can provide robust antecedent protection against cerebral ischemic injury with minimal release of pro-inflammatory cytokines, making it an ideal candidate for further clinical development. Mouse and nonhuman primate (NHP) models of cerebral ischemic injury were used to test whether an A-type CpG ODN, which induces minimal systemic inflammatory cytokine responses, can provide prophylactic protection. Extent of injury in the mouse was measured by histological staining of live tissue. In the NHP, injury was assessed 2 and 7 days post-occlusion from T2-weighted magnetic resonance images and neurological and motor deficits were cataloged daily. Plasma cytokine levels were measured using species-specific Luminex assays. Prophylactic administration of an A-type CpG ODN provided robust protection against cerebral ischemic injury in the mouse with minimal systemic inflammation. Rhesus macaques treated with D192935, a mixture of human optimized A-type CpG ODNs, had smaller infarcts and demonstrated significantly less neurological and motor deficits following ischemic injury. Our findings demonstrate the translational potential of D192935 as a prophylactic treatment for patients at risk of cerebral ischemic injury.",
keywords = "CpG ODN, Ischemia, Neuroprotection, Nonhuman primate, Preconditioning, Stroke",
author = "Frances Bahjat and {Alexander West}, G. and Steven Kohama and Christine Glynn and Henryk Urbanski and Theodore Hobbs and Eric Earl and Stevens, {Susan L.} and Mary Stenzel-Poore",
year = "2017",
month = "4",
day = "5",
doi = "10.1007/s12975-017-0532-8",
language = "English (US)",
pages = "1--12",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",

}

TY - JOUR

T1 - Preclinical Development of a Prophylactic Neuroprotective Therapy for the Preventive Treatment of Anticipated Ischemia-Reperfusion Injury

AU - Bahjat, Frances

AU - Alexander West, G.

AU - Kohama, Steven

AU - Glynn, Christine

AU - Urbanski, Henryk

AU - Hobbs, Theodore

AU - Earl, Eric

AU - Stevens, Susan L.

AU - Stenzel-Poore, Mary

PY - 2017/4/5

Y1 - 2017/4/5

N2 - Ischemia-reperfusion brain injury can be iatrogenically induced secondary to life-saving procedures. Prophylactic treatment of these patients offers a promising prevention for lifelong complications. We postulate that a cytosine-guanine (CpG) oligodeoxynucleotide (ODN) can provide robust antecedent protection against cerebral ischemic injury with minimal release of pro-inflammatory cytokines, making it an ideal candidate for further clinical development. Mouse and nonhuman primate (NHP) models of cerebral ischemic injury were used to test whether an A-type CpG ODN, which induces minimal systemic inflammatory cytokine responses, can provide prophylactic protection. Extent of injury in the mouse was measured by histological staining of live tissue. In the NHP, injury was assessed 2 and 7 days post-occlusion from T2-weighted magnetic resonance images and neurological and motor deficits were cataloged daily. Plasma cytokine levels were measured using species-specific Luminex assays. Prophylactic administration of an A-type CpG ODN provided robust protection against cerebral ischemic injury in the mouse with minimal systemic inflammation. Rhesus macaques treated with D192935, a mixture of human optimized A-type CpG ODNs, had smaller infarcts and demonstrated significantly less neurological and motor deficits following ischemic injury. Our findings demonstrate the translational potential of D192935 as a prophylactic treatment for patients at risk of cerebral ischemic injury.

AB - Ischemia-reperfusion brain injury can be iatrogenically induced secondary to life-saving procedures. Prophylactic treatment of these patients offers a promising prevention for lifelong complications. We postulate that a cytosine-guanine (CpG) oligodeoxynucleotide (ODN) can provide robust antecedent protection against cerebral ischemic injury with minimal release of pro-inflammatory cytokines, making it an ideal candidate for further clinical development. Mouse and nonhuman primate (NHP) models of cerebral ischemic injury were used to test whether an A-type CpG ODN, which induces minimal systemic inflammatory cytokine responses, can provide prophylactic protection. Extent of injury in the mouse was measured by histological staining of live tissue. In the NHP, injury was assessed 2 and 7 days post-occlusion from T2-weighted magnetic resonance images and neurological and motor deficits were cataloged daily. Plasma cytokine levels were measured using species-specific Luminex assays. Prophylactic administration of an A-type CpG ODN provided robust protection against cerebral ischemic injury in the mouse with minimal systemic inflammation. Rhesus macaques treated with D192935, a mixture of human optimized A-type CpG ODNs, had smaller infarcts and demonstrated significantly less neurological and motor deficits following ischemic injury. Our findings demonstrate the translational potential of D192935 as a prophylactic treatment for patients at risk of cerebral ischemic injury.

KW - CpG ODN

KW - Ischemia

KW - Neuroprotection

KW - Nonhuman primate

KW - Preconditioning

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85017100478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017100478&partnerID=8YFLogxK

U2 - 10.1007/s12975-017-0532-8

DO - 10.1007/s12975-017-0532-8

M3 - Article

SP - 1

EP - 12

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

ER -